574 related articles for article (PubMed ID: 32203863)
1. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
2. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.
Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Zaragoza A; Moeller A; Carlson RG
Drug Alcohol Depend; 2019 Nov; 204():107574. PubMed ID: 31568934
[TBL] [Abstract][Full Text] [Related]
3. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
[TBL] [Abstract][Full Text] [Related]
4. "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.
Silverstein SM; Daniulaityte R; Martins SS; Miller SC; Carlson RG
Int J Drug Policy; 2019 Dec; 74():76-83. PubMed ID: 31563098
[TBL] [Abstract][Full Text] [Related]
5. "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion.
McLean K; Kavanaugh PR
Int J Drug Policy; 2019 Sep; 71():118-124. PubMed ID: 31330267
[TBL] [Abstract][Full Text] [Related]
6. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Carlson RG
J Subst Use Addict Treat; 2023 Apr; 147():208973. PubMed ID: 36804351
[TBL] [Abstract][Full Text] [Related]
7. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
9. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
10. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
11. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
13. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
Butler SF; Oyedele NK; Dailey Govoni T; Green JL
JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
[TBL] [Abstract][Full Text] [Related]
14. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
15. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
[TBL] [Abstract][Full Text] [Related]
18. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
[TBL] [Abstract][Full Text] [Related]
19. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
20. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
Hughto JMW; Moyo P; Green TC
J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
